Back to top
more

Magenta Therapeutics, Inc. (MGTA)

(Delayed Data from NSDQ)

$15.33 USD

15.33
252,179

+1.53 (11.09%)

Updated May 3, 2019 04:00 PM ET

After-Market: $15.30 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: NVIDIA, Novo Nordisk, Magenta in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics

by Zacks Equity Research

Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics are included in this Analyst Blog.

Tirthankar Chakraborty headshot

Easing Banking Fears, Rate Hike Pause Boost Markets: 5 Picks

by Tirthankar Chakraborty

Thanks to the easing concerns in the banking sector and the Fed's willingness to pause rate hikes, it's wise to invest in growth stocks like Blue Bird (BLBD), Salesforce (CRM), and Deckers Outdoor (DECK).

Magenta (MGTA) Down on Pipeline Update for Leukemia Drug

by Zacks Equity Research

Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.

After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Magenta Therapeutics, Inc. (MGTA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 21% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)

by Zacks Equity Research

Magenta Therapeutics, Inc. (MGTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics

by Zacks Equity Research

Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics

Sanghamitra Saha headshot

Bet on 5 Top Stocks With Rising P/E for Spectacular Returns

by Sanghamitra Saha

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

AVROBIO's Gaucher Disease Candidate Gets Orphan Drug Status

by Zacks Equity Research

AVROBIO's (AVRO) gene therapy candidate for Gaucher disease, AVR-RD-02, gets orphan drug designation from the European Commission.

Magenta (MGTA) Looks Good: Stock Adds 5.2% in Session

by Zacks Equity Research

Magenta (MGTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Magenta Therapeutics' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Magenta Therapeutics.

Magenta Therapeutics Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Magenta Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.